Literature DB >> 11703364

Evidence of a role for CD200 in regulation of immune rejection of leukaemic tumour cells in C57BL/6 mice.

R M Gorczynski1, Z Chen, J Hu, Y Kai, J Lei.   

Abstract

Increased expression of the molecule CD200 in mice receiving renal allografts is associated with immunosuppression leading to increased graft survival, and altered cytokine production in lymphocytes harvested from the transplanted animals. Preferential production of IL-4, IL-10 and TGFbeta occurs on donor-specific restimulation in vitro, with decreased production of IL-2, IFNgamma and TNFalpha. These effects are enhanced by simultaneous infusion of CD200 immunoadhesin (CD200Fc) and donor CD200 receptor (CD200r) bearing macrophages to transplanted mice. C57BL/6 mice do not normally resist growth of EL4 or C1498 leukaemia tumour cells. Following transplantation of cyclophosphamide-treated C57BL/6 with T-depleted C3H bone marrow cells, or for the EL4 tumour, immunization of C57BL/6 mice with tumour cells transfected with a vector encoding the co-stimulatory molecule CD80 (EL4-CD80), mice resist growth of tumour challenge. Immunization of C57BL/6 mice with EL4 cells overexpressing CD86 (EL4-CD86) is ineffective. Protection from tumour growth in either model is suppressed by infusion of CD200Fc, an effect enhanced by co-infusion of CD200r+ macrophages. CD200Fc acts on both CD4+ and CD8+ cells to produce this suppression. These data are consistent with the hypothesis that immunosuppression following CD200-CD200r interaction can regulate a functionally important tumour growth inhibition response in mice.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11703364      PMCID: PMC1906195          DOI: 10.1046/j.1365-2249.2001.01689.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  37 in total

1.  Restoration of alloreactivity of melanoma by transduction with B7.1.

Authors:  M S Brady; F Lee; D D Eckels; S Y Ree; J B Latouche; J S Lee
Journal:  J Immunother       Date:  2000 May-Jun       Impact factor: 4.456

2.  Down-regulation of the macrophage lineage through interaction with OX2 (CD200).

Authors:  R M Hoek; S R Ruuls; C A Murphy; G J Wright; R Goddard; S M Zurawski; B Blom; M E Homola; W J Streit; M H Brown; A N Barclay; J D Sedgwick
Journal:  Science       Date:  2000-12-01       Impact factor: 47.728

Review 3.  Function and dysfunction of CD4(+) T cells in the immune response to melanoma.

Authors:  W H Fischer; P thor Straten; P Terheyden; J C Becker
Journal:  Cancer Immunol Immunother       Date:  1999-10       Impact factor: 6.968

Review 4.  Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy.

Authors:  R Champlin; I Khouri; S Kornblau; F Marini; P Anderlini; N T Ueno; J Molldrem; S Giralt
Journal:  Hematol Oncol Clin North Am       Date:  1999-10       Impact factor: 3.722

5.  Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro.

Authors:  A Heiser; P Dahm; D R Yancey; M A Maurice; D Boczkowski; S K Nair; E Gilboa; J Vieweg
Journal:  J Immunol       Date:  2000-05-15       Impact factor: 5.422

6.  Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function.

Authors:  G J Wright; M J Puklavec; A C Willis; R M Hoek; J D Sedgwick; M H Brown; A N Barclay
Journal:  Immunity       Date:  2000-08       Impact factor: 31.745

7.  Receptor engagement on cells expressing a ligand for the tolerance-inducing molecule OX2 induces an immunoregulatory population that inhibits alloreactivity in vitro and in vivo.

Authors:  R M Gorczynski; K Yu; D Clark
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

8.  Augmentation of antitumor immunity by genetically engineered fibroblast cells to express both B7.1 and interleukin-7.

Authors:  T S Kim; S W Chung; S Y Hwang
Journal:  Vaccine       Date:  2000-06-15       Impact factor: 3.641

9.  Modulation of the immune response to DNA vaccine by co-delivery of costimulatory molecules.

Authors:  J Fló; S Tisminetzky; F Baralle
Journal:  Immunology       Date:  2000-06       Impact factor: 7.397

10.  Vaccination with a recombinant vaccinia vaccine containing the B7-1 co-stimulatory molecule causes no significant toxicity and enhances T cell-mediated cytotoxicity.

Authors:  Y R Freund; J C Mirsalis; D G Fairchild; J Brune; L A Hokama; J Schindler-Horvat; J E Tomaszewski; J W Hodge; J Schlom; J A Kantor; C A Tyson; S J Donohue
Journal:  Int J Cancer       Date:  2000-02-15       Impact factor: 7.396

View more
  16 in total

1.  Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation.

Authors:  John R McWhirter; Anke Kretz-Rommel; Alan Saven; Toshiaki Maruyama; Kathleen N Potter; C Ian Mockridge; E Prenn Ravey; Fenghua Qin; Katherine S Bowdish
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-17       Impact factor: 11.205

2.  Bidirectional effect of CD200 on breast cancer development and metastasis, with ultimate outcome determined by tumor aggressiveness and a cancer-induced inflammatory response.

Authors:  N Erin; A Podnos; G Tanriover; Ö Duymuş; E Cote; I Khatri; R M Gorczynski
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

Review 3.  CD200-CD200R Pathway in the Regulation of Tumor Immune Microenvironment and Immunotherapy.

Authors:  Jin-Qing Liu; Aiyan Hu; Jianmin Zhu; Jianyu Yu; Fatemeh Talebian; Xue-Feng Bai
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 4.  Programmed cell removal: a new obstacle in the road to developing cancer.

Authors:  Mark P Chao; Ravindra Majeti; Irving L Weissman
Journal:  Nat Rev Cancer       Date:  2011-12-08       Impact factor: 60.716

Review 5.  Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia.

Authors:  Hanna A Knaus; Christopher G Kanakry; Leo Luznik; Ivana Gojo
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

6.  A Bone Anabolic Effect of RANKL in a Murine Model of Osteoporosis Mediated Through FoxP3+ CD8 T Cells.

Authors:  Zachary S Buchwald; Chang Yang; Suman Nellore; Elena V Shashkova; Jennifer L Davis; Anna Cline; Je Ko; Deborah V Novack; Richard DiPaolo; Rajeev Aurora
Journal:  J Bone Miner Res       Date:  2015-05-21       Impact factor: 6.741

7.  Tumor expression of CD200 inhibits IL-10 production by tumor-associated myeloid cells and prevents tumor immune evasion of CTL therapy.

Authors:  Lixin Wang; Jin-Qing Liu; Fatemeh Talebian; Hani Y El-Omrani; Mazin Khattabi; Li Yu; Xue-Feng Bai
Journal:  Eur J Immunol       Date:  2010-09       Impact factor: 5.532

8.  A Critical Role for CD200R Signaling in Limiting the Growth and Metastasis of CD200+ Melanoma.

Authors:  Jin-Qing Liu; Fatemeh Talebian; Lisha Wu; Zhihao Liu; Ming-Song Li; Laichu Wu; Jianmin Zhu; Joseph Markowitz; William E Carson; Sujit Basu; Xue-Feng Bai
Journal:  J Immunol       Date:  2016-07-06       Impact factor: 5.422

9.  mRNA expression profiling reveals a role of Helicobacter pylori vacuolating toxin in escaping host defense.

Authors:  Jian-Ping Yuan; Tao Li; Zhen-Hong Li; Gui-Zhen Yang; Bao-Yu Hu; Xiao-Dong Shi; Tie-Liu Shi; Shan-Qing Tong; Xiao-Kui Guo
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

10.  CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia.

Authors:  S J Coles; E C Y Wang; S Man; R K Hills; A K Burnett; A Tonks; R L Darley
Journal:  Leukemia       Date:  2011-01-28       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.